Lisinopril is an angiotensin converting enzyme inhibitor indicated for treatment of hypertension in adults and pediatric patients 6 years of age and older, among other approved uses. It is available as tablets and oral solution. MedsAcross supplies Lisinopril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Zestril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older. Adjunct therapy for heart failure. Treatment of Acute Myocardial Infarction
Source: US FDA prescribing information
Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium.
Source: US FDA prescribing information
Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily. Pediatric patients with glomerular filtration rate > 30 mL/min/1.73m 2: Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily. Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily. Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily. Renal Impairment: For patients with creatinine clearance ≥ 10 mL/min and ≤ 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg
Source: US FDA prescribing information
Zestril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor. Zestril is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema Do not co-administer aliskiren with ZESTRIL in patients with diabetes. Angioedema or a history of hereditary or idiopathic angioedema. Hypersensitivity. Co-administration of aliskiren with Zestril in patients with diabetes
Source: US FDA prescribing information
Boxed warning (fetal toxicity): When pregnancy is detected, discontinue ZESTRIL as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Angioedema: Discontinue Zestril, provide appropriate therapy and monitor until resolved. Renal impairment: Monitor renal function periodically. Hypotension: Patients with other heart or renal diseases have increased risk, monitor blood pressure after initiation. Hyperkalemia: Monitor serum potassium periodically. Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure
Source: US FDA prescribing information
Common adverse reactions (events 2% greater than placebo) by use: Hypertension: headache, dizziness and cough. Heart Failure: hypotension and chest pain. Acute Myocardial Infarction: hypotension
Source: US FDA prescribing information
Diuretics: Excessive drop in blood pressure. NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy. Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia. Lithium: Symptoms of lithium toxicity. Gold: Nitritoid reactions have been reported. Concomitant mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk
Source: US FDA prescribing information
Store at controlled room temperature, 20° to 25°C (68° to 77°F). Protect from moisture, freezing and excessive heat.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
13 presentations of Lisinopril, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lisinopril 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lisinopril 20 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lisinopril 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lisinopril 40 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lisinopril 2.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lisinopril 30 mg tabletOralGeneric name | — | US FDA | Available on request |
| Qbrelis 1 mg/mL oral solutionOral | Azurity Pharmaceuticals | US FDA | Available on request |
| Zestril 10 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
| Zestril 2.5 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
| Zestril 20 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
| Zestril 30 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
| Zestril 40 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
| Zestril 5 mg tabletOral | Upsher-Smith Laboratories | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 December 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Lisinopril in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 13 presentations of Lisinopril and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Lisinopril, including Qbrelis, Zestril.
Yes. The US FDA first approved Lisinopril on 29 December 1987, according to Drugs@FDA.
No listed presentation of Lisinopril is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lisinopril is classified under ATC code C09AA03 (Lisinopril).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.